{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-028110","form_type":"8-K","ticker":"RCUS","cik":"0001724521","company_name":"Arcus Biosciences, Inc.","filed_at":"2025-02-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.623478+00:00","generated_at":"2026-05-26T16:56:22.291389+00:00","sec_items":["2.02","8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Arcus reports $992M cash; Gilead opts out of casdatifan; ARC-20 data shows ORR 25-33%","bullets":["Preliminary cash, cash equivalents and marketable securities of $992M as of Dec 31, 2024.","Gilead's exclusive option for casdatifan expired without exercise; Arcus retains full global rights.","ARC-20 in ccRCC: 50mg BID median PFS 9.7 months, ORR 25%; 100mg QD ORR 33%.","Disease control rate 81-87% across cohorts; median DoR not reached; safety acceptable.","All but two of 26 responders remained on treatment; one discontinuation due to anemia."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-028110","json":"https://secwatch.observer/filing/0001193125-25-028110.json","markdown":"https://secwatch.observer/filing/0001193125-25-028110.md","text":"https://secwatch.observer/filing/0001193125-25-028110.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1724521/000119312525028110/0001193125-25-028110-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1724521/000119312525028110/d901841d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T16:56:22.291389+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}